Loading
A phase 1/2 trial of Atirmociclib and Fulvestrant in advanced solid tumours, run by Pfizer, active and no longer recruiting.
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors is a phase 1/2 interventional study registered as NCT05262400 by Pfizer, with 235 participants enrolled, started 2022-03-14 and due to reach its primary completion in 2027-02-26. Interventions recorded: PF-07220060 + PF-07104091 combination dose escalation, PF-07104091 + PF-07220060 + fulvestrant dose expansion and PF-07104091 + PF-07220060 + letrozole dose expansion.
Shares Atirmociclib, CDK4/6 inhibitors, Pfizer (incl. Seagen), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Atirmociclib, CDK4/6 inhibitors, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, CDK4/6 inhibitors, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Atirmociclib, CDK4/6 inhibitors, Pfizer (incl. Seagen) and the tag pipeline.
Shares Fulvestrant, CDK4/6 inhibitors, Pfizer (incl. Seagen) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, CDK4/6 inhibitors, Metastatic cancer (cancer that has spread) and the tag pipeline.